drugset / Trial / NCT06342310
RE104 Safety and Efficacy Study in Postpartum Depression
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-control.
Timeline
- Start
- 2024-06-14
- Primary completion
- 2025-05-22
- Completion
- 2025-06-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RE104 | Unknown | 1.5 mg | Subcutaneous |
| Subject | RE104 | Unknown | 30 mg | Subcutaneous |